Tag: Lunsumio

Home / Lunsumio

Categories

Mosunetuzumab-axgb is granted accelerated approval for relapsed or refractory follicular lymphoma

Jan 2023: Mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) following two or more ro...
lunsumio

Scan the code